Please login to the form below

Planning your clinical trial? Why you need to engage patients sooner

It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design.

COUCH Health has previously discussed the importance of understanding the patient journey here. This can help us to optimise the patient experience and make it more likely that patients will both join and remain in a clinical study. We need to think about the very beginning of each patient’s journey. Their life before the diagnosis, experiencing symptoms, the diagnosis itself and reaching a point where they can consider joining a clinical study. All with the end goal of maximising the quality of clinical research and benefitting other people in the future.

Clinical trial design

If we don’t involve patients from the very beginning of study development, how can we expect the study to be relevant to them? And if it’s not relevant, patients won’t be engaged, motivated or able to join a clinical study. If they do enrol, maybe they will end up dropping out. From inclusion and exclusion criteria to the number of assessments and appointments, patients need to be at the core of the decision-making process.

Inclusion and exclusion criteria need to be aligned with safety and ethics, and reflect the questions that researchers are looking to answer. But it is possible that the criteria for some studies are too strict; organisations are unknowingly making it even more difficult for a patient to join a study by not considering the characteristics of that patient population. If a patient and those close to them are reading information about a study, it seems obvious that they will be put off if they have to travel to the study clinic on a regular basis. Reducing the number of appointments to the fewest possible (while still being able to meet endpoints) will make patients more likely to want to join and continue taking part in a study.

Patient reported outcomes (PROs) have gained increased attention over the years; studies can raise their credibility by publishing PRO results. Most importantly, patients would often prefer to be asked about PROs than studied for physiological or pharmacological changes. PROs are more meaningful to some patients and can reflect how they truly feel about living with their condition. Poor or altered quality of life is a huge impact of many conditions and some people are more concerned by this than physiological effects.

Patient recruitment

It’s time for organisations running clinical studies to revolutionise their strategies. To maximise patient engagement, we need to stay up to date with technology and get creative. Continuing to think about the patient journey – patients are now at a point where they could join a study. Why would they want to sign up? How do they like to receive information? By making sure we know the answers to questions like these, we can increase the likelihood of successful recruitment. We need to make sure patients and their support network have enough information to fully understand the study and whether they really want to take part.

Informed consent

Informed consent forms are often lengthy, technical and complex. How can people be expected to truly engage with materials when their perspective is not considered? Can materials written and/or designed by those working in the pharmaceutical or healthcare industry be the most effective if patients have not been involved? It is paramount that clinical studies involve patients and the general public when preparing any written materials. It is not just about making a document easy to read (avoiding complex scientific terms and jargon). It is about showing understanding of what people truly want and need and what might motivate them to join a clinical study. What can you do for them?

The industry needs to do more

Engaging with patients earlier in clinical study planning should lead to clinical studies being more successful. Most importantly, it is gateway for organisations running studies to truly become patient centric.

If you want to know more about the different ways you can improve clinical study enrolment through patient centricity, download our white paper here.

This blog was first published here:

11th August 2020



Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Suite 2.10, Jactin House
24 Hood Street
M4 6WX
United Kingdom

Latest content on this profile

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need unconscious bias training.”
COUCH Health
How do ethnic minority groups in the U.S. view clinical trials?
This year, we decided to do the same with ethnic minority communities over in the United States (U.S.) too. Ultimately, we wanted to explore attitudes towards clinical trials from these communities, understand the barriers in participation, and determine what factors may influence people’s decisions to take part.
COUCH Health
Three things to consider when using social listening research for patient recruitment
We are looking at how patient research can power your patient recruitment campaign. A look into social listening follows on from this blog perfectly, offering a stronger and more authentic alternative to relying on data trends to guide your activities. So, let’s get started…
COUCH Health
4 ways mobile ethnography studies can elevate your patient insights
How can we achieve more real-life, in-the-moment insights from different groups to understand their thoughts and behaviours? This is where ethnography studies come in.
COUCH Health
#DemandDiversity: We’re calling on the clinical trials industry to include us all
The lack of diversity in clinical trials is something we’ve spoken about time and time again. By now, you might think we sound a bit like a broken record. But, the fact is, many people still aren’t aware of the underrepresentation, especially those who don’t work in the industry. Do you think if the clinical research industry could see the people they were leaving out of clinical trials, and hear how they felt about being underrepresented, it would make a difference?
COUCH Health
Include Us All in Your Clinical Trials

COUCH Health